dc.contributor.author
Spreckelmeyer, Sarah
dc.contributor.author
Balzer, Matthias
dc.contributor.author
Poetzsch, Simon
dc.contributor.author
Brenner, Winfried
dc.date.accessioned
2022-06-13T09:44:58Z
dc.date.available
2022-06-13T09:44:58Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/35265
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-34983
dc.description.abstract
Background: [68Ga]Ga-FAPI-46 is a promising radiopharmaceutical for in vivo detection of the fibroblast activation protein by positron emission tomography. Until now, the synthesis of [68Ga]Ga-FAPI-46 has been only performed manually. Our aim was to evaluate the automated synthesis of this radiopharmaceutical on two different commercially available synthesis modules in order to make the tracer readily available for clinical application.
Results: The synthesis of [68Ga]Ga-FAPI-46 with different amounts of precursor (10-50 μg) on the Modular Lab PharmTracer (MLPT) and Modular Lab eazy (ML eazy) from Eckert & Ziegler with a customized synthesis template and a customized single-use cassette yielded best results with 50 μg FAPI-46 for clinical multi-dose application. All relevant quality control parameters tested (e.g. sterility, stability and radiochemical purity) were in accordance with the European Pharmacopoeia.
Conclusions: [68Ga]Ga-FAPI-46 was successfully synthesized fully-automated on the synthesis modules Modular Lab PharmTracer and ML eazy and is, thus, available for multi-dose application in clinical settings.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Automated production
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Fully-automated production of [68Ga]Ga-FAPI-46 for clinical application
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
31
dcterms.bibliographicCitation.doi
10.1186/s41181-020-00112-x
dcterms.bibliographicCitation.journaltitle
EJNMMI Radiopharmacy and Chemistry
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.volume
5
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
33331982
dcterms.isPartOf.eissn
2365-421X